Health knowledge made personal
Join this community!
› Share page:
Search posts:

Subgenomic Replicons of the Flavivirus Dengue

Posted Feb 27 2011 7:00pm

Description of Invention:
Dengue virus, with its four serotypes Den-1 to Den-4, is the most important member of the Flavivirus genus with respect to infection of human producing diseases that range from flu-like symptoms of dengue fever (DF) to severe or fatal illness of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Dengue outbreaks continue to be a major public health problem in densely populated areas of the tropical and subtropical regions, where mosquito vectors are abundant. This invention relates to the construction of all four types of dengue subgenomic replicons (chromosome and plasmid which contain genetic information necessary for their own replication) containing large deletions in the structural region (C-preM-E) of the genome. Immunization using these replicons should be effective in eliciting not only a humoral-mediated immune response but also a cell-mediated immune response. These replicons should be safer than a live attenuated vaccine because they cannot cause disease in the host and they should be better than subunit vaccines because they can replicate in the host.

Prevention of severe and/or fatal human disease caused by dengue virus, a major health concern in tropical and subtropical regions

Xiaowu Pang (FDA)

Patent Status:
HHS, Reference No. E-228-2000/0
US, , Patent No. 7,524,508, Issued 28 Apr 2009
PCT, Application No. PCT/US02/06962 filed 21 Feb 2002
US, Application No. 12/394,822 filed 27 Feb 2009

Licensing Status:
Available for non-exclusive or exclusive licensing.

Infectious Diseases
Infectious Diseases - Vaccines

For Licensing Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Phone: 301-435-4646
Fax: 301-402-0220

Ref No: 502

Updated: 02/2011

Post a comment
Write a comment:

Related Searches